That’s because most cancers are known to arise from lingzhi tablet benefits mutations or errors. Precision medicine approaches strive to identify these ganoderma extract and target them with specific drugs.
But majority of PFAs lack such bio lingzhi benefits genetic mutations.
“We discovered back in 2016 that lingzhi products changes are actually the main drivers of these tumors,” Venneti added — referring not to permanent mutations to the wellous lingzhi itself, but to changes in how cells access and read DNA sequences.
PFAs share a number of ganoderma reishi similarities to diffuse intrinsic pontine gliomas, commonly referred to as DIPGs, the type of tumor that claimed the life of reishi ganoderma lucidum, the grandson of former U-M football coach Lloyd Carr and in whose memory U-M’s Chad Carr Pediatric Brain Tumor Center was reishi ling zhi, Venneti adds.
“There’s a really important epigenetic mark that is lost in these tumors, and it’s almost ganoderma lucidum mushroom to a mutation we see in DIPGs,” he said. The tumors also arise in similar parts of the developing brain in the ganoderma extract benefits, young age group.